Vijay Pande, once a Stanford chemistry professor, now runs a boutique firm with a handful of concentrated bets, signaling a shift in the biotech industry. As AI offers more precise drug development, the future may involve fewer, better-targeted investments, reversing the trend of widespread, costly bets.

Drugs can now be engineered rather than discovered by chance, thanks to AI and machine learning. However, the path from digital models to clinical trials remains challenging, especially given the high failure rate and reliance on animal models, which are not always predictive of human responses.

Biology’s move from a science of discovery to one of engineering promises more personalized medicine. Yet, the lack of freely available biological data poses a unique challenge for AI development, as each company must build its own dataset, limiting the sharing and cross-disciplinary collaboration that could speed up progress.

Pande’s pivot to a smaller, more focused firm reflects a broader trend in the tech industry, where smaller, more agile companies are increasingly outperforming large, slow-moving ones. As AI continues to transform medicine, it will be fascinating to see how these smaller firms can navigate the complex landscape of data and innovation.